The Hidden Costs of the Vaccine Cold Chain

In this episode, Stefan Lutzmayer, from IQVIA’s EMEA Thought Leadership team, speaks with Özgür Tuncer, CEO & Executive Director of Stablepharma, about the growing complexity of the pharmaceutical cold chain and how innovation could make it more resilient, sustainable, and accessible.

IQVIA’s EMEA Thought Leadership team analyses major trends shaping the pharmaceutical market and their implications for healthcare systems and companies across the region.

You’ll hear about:

• Why “keeping it cold” is more than logistics—it’s about safety, equity and sustainability.
• Where breakdowns happen in practice, from transport to site of administration.
• Why the cold chain is not just an issue of low- and middle-income countries.
• How hidden costs and emissions make the cold chain a big topic for healthcare systems around the world.
• The promise of thermostable technology to reduce waste, cut costs and expand access globally.

Listen in for practical insights on how the next decade of cold-chain innovation could reshape the future of biologics and global health.

For more insights, read IQVIA’s white paper “Tip of the Iceberg: Economic and Environmental Impact of the Vaccine Cold Chain.”